The Quarter story
The two most recent quarterly results, compared side-by-side.
Neogen Chemicals rebounds with strong revenue and profit recovery, driven by inorganic segment growth, while managing rising interest costs and margin pressure.
Consolidated revenue grows from ₹186.7 Cr to ₹250 Cr from Q1 FY26 to Q1 FY27 — strong demand recovery drives top-line expansion.
Standalone interest expense rises from ₹13.1 Cr to ₹22.9 Cr from Q3 FY25 to Q3 FY26 — higher debt servicing costs pressure cash flow.
Consolidated profit after tax rebounds from ₹3.4 Cr to ₹17 Cr from Q2 FY26 to Q1 FY27 — bottom-line turnaround gains momentum.
Standalone PAT margins fall from 7.7% to 4.1% from Q1 FY26 to Q3 FY26 — margin compression reflects input cost pressures.
Inorganic Chemicals revenue surges from ₹22 Cr to ₹57 Cr from Q1 FY26 to Q1 FY27 — segment expansion fuels overall growth.
Standalone PBT margins drop from 10.3% to 5.5% from Q1 FY26 to Q3 FY26 — cost inflation weighs on pre-tax profitability.
Product portfolio expands from 246 items to 258 items from Q3 FY25 to Q1 FY27 — broader offerings support market reach.
Standalone expenditure increases from ₹149.9 Cr to ₹179.3 Cr from Q1 FY26 to Q3 FY26 — capacity expansion drives higher operational spend.
Consolidated EBITDA climbs from ₹30.0 Cr to ₹48 Cr from Q2 FY26 to Q1 FY27 — operational leverage improves with volume recovery.
Standalone earnings per share declines from ₹5.46 to ₹3.32 from Q3 FY25 to Q3 FY26 — per-share profit pressure continues amid cost rises.
NSE
BSE
